Depression Outpatient – Cybin 003-002
About the Study
For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).
The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.
This study is sponsored by Cybin.
Eligibility
You may be eligible to participate in this study if you:
are between the ages of 18-85 years old
meet DSM-5 criteria for Major Depressive Disorder (MDD) diagnosis
are currently on a stable dose of anti-depressant medication for at least 4 weeks, with inadequate response
are able to remain in our private suite for the entire dosing session (up to 8 hours) for each dosing day
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.